What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Immune system
Drew M. Pardoll mostly deals with Immunology, Immune system, T cell, Cell biology and Antigen.
His Cancer research extends to Immunology, which is thematically connected.
His Immune system research is multidisciplinary, incorporating perspectives in Receptor, Cancer research and Antibody.
His T cell study combines topics from a wide range of disciplines, such as Cytotoxic T cell, T lymphocyte, CD8 and Immune tolerance.
His studies deal with areas such as Transcription factor, MHC class I, Major histocompatibility complex, Macrophage polarization and Antigen presentation as well as Cell biology.
The study incorporates disciplines such as Recombinant DNA and Virology in addition to Antigen.
His most cited work include:
- Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. (922 citations)
- Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 (915 citations)
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape (882 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Immunology, Cancer research, Immune system, Immunotherapy and T cell.
His Immunology study incorporates themes from Cancer and Cytotoxic T cell.
His Cancer research research is multidisciplinary, relying on both Immune checkpoint, Prostate cancer and Carcinogenesis.
He has researched Immune system in several fields, including Signal transduction and Antibody.
His study in Immunotherapy is interdisciplinary in nature, drawing from both Blockade, Oncology and Glioma.
His research integrates issues of Molecular biology, Receptor, Immune tolerance and Cell biology in his study of T cell.
He most often published in these fields:
- Immunology (42.02%)
- Cancer research (32.90%)
- Immune system (30.62%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (32.90%)
- Immunotherapy (19.22%)
- Immune system (30.62%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Immunotherapy, Immune system, Immune checkpoint and Cancer.
His Cancer research research includes elements of T cell, Cytotoxic T cell and Prostate cancer.
His T cell study incorporates themes from Cell culture, Antigen and Cancer immunology.
Drew M. Pardoll studies Immune system, focusing on Antigen presentation in particular.
His Cancer research integrates issues from Medical physics, Mutant and Oncology.
His studies deal with areas such as Immunology, Receptor and Avidity as well as Transfection.
Between 2017 and 2021, his most popular works were:
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (622 citations)
- Neoadjuvant checkpoint blockade for cancer immunotherapy (99 citations)
- Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy (94 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Immune system
His primary areas of study are Cancer research, Immune system, Immunotherapy, Tumor microenvironment and Internal medicine.
His Cancer research study combines topics from a wide range of disciplines, such as Cell, Biological activity, In vitro, Cytokine and Immunity.
His Immune system research is multidisciplinary, relying on both Extracellular matrix, Signal transduction, Cell biology and Regenerative medicine.
The study incorporates disciplines such as T cell, Blockade, Melanoma and Antigen in addition to Immunotherapy.
His T cell research incorporates elements of Dendritic cell and Cancer immunology.
Drew M. Pardoll interconnects Small interfering RNA, Gene knockdown, In vivo and Cancer immunotherapy in the investigation of issues within Tumor microenvironment.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
